Actively Recruiting
Mecobalamin to Prevent Peripheral Neuropathy in Patients Receiving Taxane Chemotherapy for Solid Tumors
Led by Qinghai Red Cross Hospital · Updated on 2026-04-30
326
Participants Needed
4
Research Sites
8 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating whether oral mecobalamin can prevent or reduce chemotherapy-induced peripheral neuropathy CIPN in patients with solid tumors receiving taxane-based chemotherapy. This prospective, multicenter, open-label randomized controlled trial focuses on the common side effects of numbness, tingling, or pain in the hands and feet that some patients experience during taxane chemotherapy. The study aims to compare outcomes between those taking mecobalamin and those receiving no routine mecobalamin prevention.
CONDITIONS
Brief Title
Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy
Research Team
J
Jiuda Zhao, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
